Strong Launches Will Help BMS Win The LOE Battle In 2023 And Beyond
Three New Drugs Reached US Market In 2022
Executive Summary
Bristol Myers Squibb brought the last of nine new drugs to market last year – all needed to help it overcome three big losses of exclusivity this decade – so the focus this year is commercial execution.
You may also be interested in...
BMS Revs R&D Engine To Advance 10 New Drug Candidates Annually
Bristol aims to bring more drugs into the clinic as fast as possible without compromising on quality, with many novel molecules emerging from its productive protein degradation and cell therapy platforms.
BMS Speeding Six More Programs Into Late-Stage R&D
With big losses of exclusivity later in this decade, Bristol is looking to boost the number of products in its portfolio by 2030 even beyond the $35bn-plus in new revenue it already expects to bring in.
First Round Of Drugs Up For Medicare Negotiation Gets Soft Landing
Big pharma valuations mostly held steady as CMS released its list of the first 10 drugs subject to Medicare negotiations under the Inflation Reduction Act, which held few surprises and included products nearing the end of their patent lives by the time negotiated pricing takes effect.